Today: 30 June 2026
Barrick Mining stock drops before the bell as gold tumbles and JPMorgan weighs in
30 January 2026
2 mins read

Barrick Mining stock drops before the bell as gold tumbles and JPMorgan weighs in

New York, Jan 30, 2026, 07:34 EST — Premarket

  • Shares of Barrick Mining dropped roughly 5% in premarket action following a weak finish on Thursday.
  • Gold dropped under $5,000 an ounce, falling back from its recent record peak.
  • JPMorgan kicked off coverage with an Overweight rating ahead of Barrick’s Feb. 5 earnings report.

Barrick Mining Corp (NYSE: B) shares dropped 5.4% to $49.26 in premarket trading by 7:18 a.m. EST on Friday, following a 1.8% decline to $52.05 at Thursday’s close.

Gold prices plunged over 8%, dipping briefly under $5,000 an ounce after peaking at a record $5,594.82 on Thursday, Reuters reported. Hamad Hussain from Capital Economics pointed to the anticipated Federal Reserve shift as a key factor, saying it “appears to have put downward pressure on precious metals prices.” Reuters

President Donald Trump on Friday named former Fed Governor Kevin Warsh to head the U.S. central bank after Jerome Powell’s term expires in May, Reuters reported. Traders quickly factored this unexpected choice into rate and dollar market moves.

Gold miners took a hit in the previous session as metal prices pulled back. Barrick, Newmont, Agnico Eagle, Kinross, and AngloGold Ashanti all dropped Thursday. Some silver-focused miners saw even steeper declines, according to .

JPMorgan analyst Bennett Moore kicked off coverage of Barrick with an Overweight rating and set a $68 price target, highlighting the company’s “world-class reserve base” and exposure to gold and copper, according to StreetInsider. Overweight means the stock is expected to outperform its sector or peers. StreetInsider.com

Barrick is gearing up for a key event next week. The company plans to unveil its full-year and fourth-quarter 2025 results ahead of market open on Feb. 5 at 6:00 a.m. ET. A webcast and presentation will follow at 11:00 a.m. ET.

Consensus is set on the optimistic side. According to Zacks Equity Research on Nasdaq.com, analysts predict quarterly earnings of $0.89 per share with revenue hitting $4.78 billion. They also highlighted that Barrick has surpassed EPS estimates in three of the last four quarters.

Barrick’s U.S. shares now trade under the ticker “B” following a 2025 name change. The miner switched its NYSE symbol from “GOLD” to “B,” but it kept “ABX” on the Toronto exchange, the company said then. Barrick Mining Corporation

The plan isn’t straightforward. Barrick’s attempt to spin off its North American assets depends heavily on approvals from Newmont, its joint venture partner in Nevada, according to documents Reuters reviewed. This adds a fresh layer of execution risk on top of the usual gold price swings.

Barrick is shaking up its leadership ahead of results, naming board member Helen Cai as CFO starting March 1. She’ll replace Graham Shuttleworth, who’s expected to exit after the company releases its year-end figures on Feb. 5, Reuters reported.

Traders are watching for the next shift in bullion prices and how the market responds to Warsh’s nomination. For Barrick investors, the key date is Feb. 5, when results drop at 6:00 a.m. ET along with management’s update on costs, production, and restructuring plans.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Intuit stock price dips as AI fears circle TurboTax, but RBC sticks with $850 target
Previous Story

Intuit stock price dips as AI fears circle TurboTax, but RBC sticks with $850 target

C3.ai stock price slips in premarket as Automation Anywhere merger-talk report lingers
Next Story

C3.ai stock price slips in premarket as Automation Anywhere merger-talk report lingers

Go toTop